drugset / Trial / NCT05027906
Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the safety, PK, and efficacy of AT 1501 in patients undergoing kidney transplantation.
Timeline
- Start
- 2022-02-18
- Primary completion
- 2027-01
- Completion
- 2027-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tegoprubart | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.